This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on november 12, 2018.(b)(4).The actual sample was received and visually inspected.It was rinsed and dried.The blood phase was filled with water and subjected to 200kpa.No leak form the fiber bundle was confirmed.The actual sample was verified to be the normal product.The reported leak may have occurred at one of the joints between the tubes and ports, which was interpreted as a leak from the fiber bundle.With the actual sample being verified to be the normal product, the cause of the leak cannot be identified.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|